Shuttle Pharmaceuticals Holdings (SHPH) Short term Debt (2025 - 2026)
Shuttle Pharmaceuticals Holdings' (SHPH) quarterly Short term Debt came in at $4.4 million in Q1 2026, little changed quarter-over-quarter from $4.4 million in Q4 2025.
Shuttle Pharmaceuticals Holdings (SHPH) Short term Debt (2025 - 2026) Analysis & Trends
Shuttle Pharmaceuticals Holdings' Short term Debt history runs 2 years deep, the most recent figure standing at $4.4 million for Q1 2026.
- On a quarterly basis, Short term Debt changed N/A year-over-year to $4.4 million in Q1 2026; TTM through Mar 2026 was $4.4 million, a N/A change from a year earlier, with the FY2025 full-year figure at $4.4 million, changed N/A from the prior year.
- Short term Debt held at $4.4 million in Q1 2026 per SHPH's latest filing, from $4.4 million in the prior quarter.
- Across five years, Short term Debt topped out at $4.4 million in Q4 2025 and bottomed at $4.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Shuttle Pharmaceuticals Holdings | 120,186.04 | 120,186.04 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.44 Mn |
| Dec 31, 2025 | 4.44 Mn |